DUPIXENT Significantly Decreased SNOT-22 Score vs Placebo as Early as Week 4, With Continued Improvement at Weeks 24 and 52 (Key Secondary Endpoints)1,a

SINUS-52 SNOT-22 SCORE REDUCTION THROUGH WEEK 52
54%

SNOT-22 SCORE IMPROVEMENT AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (-27.77 from a baseline score of 51.02) vs 19% improvement with placebo + INCS (n=153) (-10.40 from
a baseline score of 53.48) (LSM difference: -17.36 [95% CI: -20.87, -13.85]) in SINUS-521

39%

SNOT-22 SCORE IMPROVEMENT SEEN AS EARLY AS WEEK 4 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (-19.77 from a baseline score of 51.02) vs 16% improvement with placebo + INCS (n=153) (-8.35 from a baseline score of 53.48) (LSM difference: -11.41 [95% CI: -14.78, -8.05]) in SINUS-521

Turn to DUPIXENT to improve a range of CRSwNP symptoms and QoL measures2

22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0 to 110): reduced score indicates improvement.

a SNOT-22 includes 22 items assessing symptoms and symptom impact associated with CRSwNP. SNOT-22 had a 2-week recall period. The meaningful clinically important difference is 8.9.

QoL, quality of life.

SEE NSAID-ERD RESULTS
BACK TO NASAL POLYPS SCORE

Dosage and Administration

See the recommended dosing and administration options for patients on DUPIXENT.